EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro.

doi:10.1016/j.atherosclerosis.2005.02.028

Article

EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro.

Atherosclerosis - 1 Dec 2005

Ireland H, Konstantoulas C J, Cooper J A, Hawe E, Humphries S E, Mather H, Goodall A H, Hogwood J, Juhan-Vague I, Yudkin J S, di Minno G, Margaglione M, Hamsten A, Miller G J, Bauer K A, Kim Y T, Stearns-Kurosawa D J, Kurosawa S

Abstract excerpt

We have progressively analysed three studies of coronary heart disease (CHD) for a variant in EPCR (Ser219Gly). Initially, in a prospective study, NPHSII, while no overall CHD-risk was identified in heterozygotes, homozygotes for 219Gly exhibited a three-fold elevated risk (HR 3.3, CI 1.22-8.96). In diabetics within NPHSII, there was a suggestion that 219Gly+ was associated with elevated CHD-risk (HR 1.89, CI...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro.

Abstract excerpt

Topics

Related research